Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
DeviceEUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
NCT Number: NCT02307253
This study evaluates the feasibility, safety and accuracy of a 19 gauge (19G) needle in nitinol in the performance of endoscopic ultrasound (EUS) guided transduodenal biopsy for the acquisition of samples for histologic analysis. Patients with lesions that can be approached only from the duodenum will be prospectively enrolled.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Clinique du Trocadero, Paris, France
A 19 gauge needle in nitinol (Flex needle) has been recently become available for EUS guided procedure.
The use of nitinol should guarantee a better needle flexibility with a theoretical advantage on the use of this needle for lesions that need to be sampled through the duodenum. Moreover, samples for histologic examination seems to be easy to interpret than cytologic ones allowing evaluate of the overall architecture of the tissue, better performance of immunohistochemical staining, and may be of additional value to perform tissue profiling that in the future will be very important to guide individualized therapies
The existing data on the performance of the Flex needle for EUS-guided transduodenal biopsy are coming form a single study performed in one single center. Thus, the reproducibility of these results is unknown and multicenter prospective studies are warranted to answer this important question.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
A. Age greater than 18 and less than 90. B. Presence of a solid lesion of the gastrointestinal tract adjacent to the duodenum with no previous tissue diagnosis.
C. Absence of an uncorrectable coagulopathy as defined by abnormal prothrombin time (PT) or partial thromboplastin time (PTT) that does not normalize after administration of fresh frozen plasma.
D. Informed consent is obtained.
Exclusion criteria
A. Presence of an uncorrectable coagulopathy as defined by abnormal prothrombin time (PT) or partial thromboplastin time (PTT) that does not normalize after administration of fresh frozen plasma.
B. Altered anatomy of the upper gastrointestinal tract due to surgery of the esophagus, stomach and duodenum.
C. They are unable to understand and/or read the consent form.
EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
Time frame: Intraoperative
Number of patients in which it was possible to place the needle within the target lesion by a transduodenal route divided by the total number of enrolled patients.
Time frame: intraoperative and within 3 days after the procedure
rate of complications, divided in procedural complication (perforation, bleeding) occurring during the procedure and late complications (delayed bleeding, infection) occurring during the post-procedural observational period
Time frame: 5 days
percentage of patients in whom a histologically interpretable specimen will be retrieved
Time frame: 6 months
rate of correct diagnosis obtained through analysis of the tissue samples acquired with EUS fine needle biopsy
Catholic University of the Sacred Heart
Other
EUS-guided Fine Needle Tissue Acquisition Using a Newly Developed Nitinol Ultra Flex 19 Gauge Needle for Transduodenal Lesions: a Multicenter Prospective Feasibility Study
Acronym: NIFLEX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04032951
Abdominal Neoplasms, Neoplasms
Palermo, Italy
View Trial DetailsNCT03002909
Abdominal Neoplasms, Neoplasms
Asyut, Egypt
View Trial DetailsNCT02653469
Abdominal Neoplasms, Female Urogenital Diseases
Seoul, South Korea
View Trial DetailsNCT00186953
Abdominal Neoplasms, Neoplasms
Memphis, Tennessee, United States
View Trial Details